Key Takeaways
- Deepens RNAi pipeline: Novartis expands its cardiovascular and metabolic portfolio with multi-asset siRNA access from Argo, including Phase 2 and discovery-stage candidates.
- Flexible deal structure: Profit & Loss sharing in U.S. and China plus ex-China licensing rights highlight Novartis’ global growth strategy.
- Strategic positioning: Strengthens Novartis’ innovation leadership in cardiometabolic diseases, an area responsible for one-third of global mortality.
Expanding RNAi Leadership in Cardiovascular and Metabolic Diseases
Novartis is reinforcing its strategic focus on cardiovascular and metabolic innovation through a multi-asset agreement with Argo Biopharma. Building on prior collaborations, this third transaction grants Novartis expanded access to siRNA-based medicines, an emerging therapeutic class that aligns with its long-term strategy to deliver durable, disease-modifying treatments.
Multi-Asset Pipeline Integration
The deal secures an option on Argo’s Phase 2 ANGPTL3 program for dyslipidemia, alongside two discovery-stage molecules targeting severe hypertriglyceridemia and mixed dyslipidemia. Additionally, Novartis gains ex-China rights and Profit & Loss sharing potential for an IND-stage hepatic siRNA candidate expected to begin global trials in 2026.
Strategic Deal Structure with Long-Term Value
Novartis’ approach balances immediate access with long-term optionality. Argo receives $160 million upfront, while Novartis commits to option and milestone payments of up to $5.2 billion, plus royalties. The flexible Profit & Loss sharing model across key geographies underscores Novartis’ strategy to co-develop and commercialize globally while mitigating risk.
Reinforcing Novartis’ Global Cardiovascular Vision
With cardiovascular diseases causing 20.5 million deaths globally in 2021, Novartis is advancing its mission to address the world’s leading health challenge. By expanding into RNAi therapeutics, Novartis is positioning itself at the forefront of next-generation precision therapies, complementing its existing cardiovascular and metabolism portfolio while delivering transformative solutions for patients worldwide.
About Novartis
Novartis AG (NYSE: NVS) is a leading global medicines company, reimagining medicine to improve and extend people’s lives. Leveraging science-based innovation and digital technologies, Novartis delivers transformative treatments across therapeutic areas including cardiovascular, oncology, immunology, and neuroscience. The company’s portfolio includes more than 50 marketed medicines reaching nearly 800 million people globally.
About Argo Biopharma
Argo Biopharmaceutical Co., Ltd. is a clinical-stage biotechnology company developing next-generation RNAi therapeutics for cardiometabolic, viral, and rare diseases. With six therapeutic candidates in clinical development, Argo leverages global R&D and commercial expertise across Asia, the United States, and Europe to advance siRNA therapies designed for durable efficacy, differentiated safety, and improved patient adherence.
By
